Not provided
Not provided
Not provided
Not provided
Not provided
Drug withdrawal
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | Rofexocib 25 mg OD, 1 year treatment |
|
| 2 | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rofecoxib | Drug |
| ||
| placebo |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dept of Medicine, Rikshospitalet | Oslo | Oslo | 0027 | Norway |
Not provided
| ID | Term |
|---|---|
| C116926 | rofecoxib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
placebo pills |
|